Saturn V Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Saturn V Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-153,147	Closed	-$4.36M	–	23
2025 Q3	$4.36M	Sell	153,147 -67,548	-31%	-$1.62M	0.96%	17
2025 Q2	$4M	Buy	220,695 +104,342	+90%	+$1.9M	1.62%	20
2025 Q1	$2.38M	Buy	116,353 +16,353	+16%	+$364K	1.2%	18
2024 Q4	$2.57M	Buy	+100,000	New	+$2.12M	1.01%	22

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Saturn V Capital Management's NAMS Position: Q4 2025 in Review

Saturn V Capital Management sold out of NewAmsterdam Pharma (NAMS) in Q4 2025, closing a stake of 153,147 shares — an estimated $4.36M sold.

Saturn V Capital Management first reported a position in NAMS in Q4 2024 and held it in 4 quarters. The position peaked at $4.36M in Q3 2025. 186 funds tracked by Wall St. Rank hold NAMS as of Q4 2025.

Saturn V Capital Management reported no remaining NewAmsterdam Pharma position as of Q4 2025 after selling out during the quarter.
Saturn V Capital Management sold 153,147 NewAmsterdam Pharma shares in Q4 2025, an estimated $4.36M.
Saturn V Capital Management first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 4 quarters.
Saturn V Capital Management's NewAmsterdam Pharma position peaked at $4.36M in Q3 2025.
186 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2025.

Based on Saturn V Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.